Tranexamic Acid (TXA) Dosing in Primary Total Knee Arthroplasty - Wesley Research Institute
Wesley Research Institute
Donate
Now

The purpose of the study is to evaluate a product called Tranexamic Acid (TXA) and its best use in patients who are undergoing total knee replacement.

Research Objectives

Status

Current

Recruitment

Open

Estimated completion

December 2023

Patient Group

Patients undergoing total knee replacement surgery (arthroplasty)

Total Participants

80

Study location

Wesley Research Institute, Griffith University

Study type

Investigator Initiated
find out if you’re eligible

Lead investigator

  • A/Prof Susan Clark

Experienced investigator

  • Prof Robert Ware

Clinical trial coordinator

  • Emma Brownrigg

Technical title

A Prospective, Randomised Non-Blinded Pilot Study to Optimise Oral Tranexamic Acid Dosing in Primary Total Knee Arthroplasty (TXA002)

About this research project

The purpose of the study is to evaluate a product called Tranexamic Acid (TXA) and its best use in patients who are undergoing total knee replacement. The product is currently used to reduce bleeding during and after surgical procedures. This can lessen the chance of you needing a blood transfusion and may decrease pain, swelling and recovery time following the operation. Tranexamic Acid is already routinely used by surgeons for patients having joint replacements but there is currently no accurate information about the best dosing of the drug to achieve optimal patient outcomes. This study will assess whether different treatment durations will lead to better results for patients.

Latest News

Breath of fresh air for Clinical Trial participant, Tim

Husband and father of three Tim, was diagnosed with Chronic Obstructive Pulmonary Disease, sometimes known as emphysema, in 2019, when he was 56 years old.  Tim participated in a trial for patients with severe emphysema, undergoing two minimally invasive procedures, aimed at improving his lung function. 

Coeliac Disease Webinar Series

Are you or a loved one living with coeliac disease? Join us for an engaging and informative webinar designed to explore the challenges, breakthroughs and future pathways in managing this complex disease. Kicking off on Tuesday, 28 January 2025, the first webinar, Living with Coeliac Disease – Pathways to Treatment.

QSBC researchers shine at Multi-Omics 2024!

Queensland Spatial Biology Centre researchers had an action-packed few days at the Multi-Omics 2024 conference held in Brisbane last week.
1 2 3 17
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram